R01AG073480
Project Grant
Overview
Grant Description
Modulation of Hippocampal Circuitry and Memory Function with Focused Ultrasound in Amnestic MCI - Abstract
For patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD), there are few effective treatments for memory enhancement. Strategies that directly manipulate neural activity are promising but currently have serious limitations.
Deep brain stimulation (DBS) of the entorhinal cortex (ERC), a part of the brain important for memory, has been shown to improve memory in a small sample of patients. However, DBS is highly invasive and requires neurosurgery. Other neuromodulation techniques that do not require surgery are limited in that they target only surface brain structures. In MCI and AD, it is the deep brain structures, including the ERC and the hippocampus (HC), that are most affected.
Low intensity focused ultrasound pulsation (LIFUP) uses acoustic energy waves with frequencies higher than humans can hear to penetrate the skull and effect specifically targeted deep brain regions. Therefore, LIFUP could be targeted at the deep brain structures critical for episodic memory formation, the same regions that are affected in MCI and AD.
We are the first to do just this, and our preliminary data shows that LIFUP increases perfusion of the ERC, increases functional connectivity of the ERC/HC memory network, and may improve behavioral memory performance. Our LIFUP set-up is safe to use inside a magnetic resonance imaging (MRI) machine, which allows for simultaneous brain modulation and real-time measurement of the modulation using MRI.
We will use each participant's structural brain MRI to aim LIFUP at the ERC. This will allow us to directly test the effects of LIFUP on activity in the ERC, in other brain regions connected to the ERC (e.g. HC), as well as on blood flow in the HC and other brain areas important for memory.
Applying this to patients with MCI, we will try to determine the dose, booster effect, and duration of LIFUP effects on brain and blood flow, structure and function. We will also determine whether these LIFUP-related changes improve memory in this population and evaluate the effect of LIFUP on blood-based biomarkers of AD-related neurodegeneration.
Understanding how the parameters of LIFUP dose and booster session affect the impact and duration of LIFUP on brain, biomarker, and memory performance will be a significant step towards constructing a comprehensive clinical trial. The ability to change the activity and blood flow of brain regions by targeting them with LIFUP would be an important step towards developing a non-invasive memory prosthetic that would make a very significant contribution to AD treatment.
For patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD), there are few effective treatments for memory enhancement. Strategies that directly manipulate neural activity are promising but currently have serious limitations.
Deep brain stimulation (DBS) of the entorhinal cortex (ERC), a part of the brain important for memory, has been shown to improve memory in a small sample of patients. However, DBS is highly invasive and requires neurosurgery. Other neuromodulation techniques that do not require surgery are limited in that they target only surface brain structures. In MCI and AD, it is the deep brain structures, including the ERC and the hippocampus (HC), that are most affected.
Low intensity focused ultrasound pulsation (LIFUP) uses acoustic energy waves with frequencies higher than humans can hear to penetrate the skull and effect specifically targeted deep brain regions. Therefore, LIFUP could be targeted at the deep brain structures critical for episodic memory formation, the same regions that are affected in MCI and AD.
We are the first to do just this, and our preliminary data shows that LIFUP increases perfusion of the ERC, increases functional connectivity of the ERC/HC memory network, and may improve behavioral memory performance. Our LIFUP set-up is safe to use inside a magnetic resonance imaging (MRI) machine, which allows for simultaneous brain modulation and real-time measurement of the modulation using MRI.
We will use each participant's structural brain MRI to aim LIFUP at the ERC. This will allow us to directly test the effects of LIFUP on activity in the ERC, in other brain regions connected to the ERC (e.g. HC), as well as on blood flow in the HC and other brain areas important for memory.
Applying this to patients with MCI, we will try to determine the dose, booster effect, and duration of LIFUP effects on brain and blood flow, structure and function. We will also determine whether these LIFUP-related changes improve memory in this population and evaluate the effect of LIFUP on blood-based biomarkers of AD-related neurodegeneration.
Understanding how the parameters of LIFUP dose and booster session affect the impact and duration of LIFUP on brain, biomarker, and memory performance will be a significant step towards constructing a comprehensive clinical trial. The ability to change the activity and blood flow of brain regions by targeting them with LIFUP would be an important step towards developing a non-invasive memory prosthetic that would make a very significant contribution to AD treatment.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Los Angeles,
California
900958348
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 07/31/26 to 07/31/27 and the total obligations have increased 399% from $621,961 to $3,100,642.
Los Angeles University Of California was awarded
Enhancing Memory Function in MCI Patients with Focused Ultrasound Modulation
Project Grant R01AG073480
worth $3,100,642
from National Institute on Aging in August 2021 with work to be completed primarily in Los Angeles California United States.
The grant
has a duration of 6 years and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity Early Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 5/21/26
Period of Performance
8/15/21
Start Date
7/31/27
End Date
Funding Split
$3.1M
Federal Obligation
$0.0
Non-Federal Obligation
$3.1M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01AG073480
Additional Detail
Award ID FAIN
R01AG073480
SAI Number
R01AG073480-3280688714
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
RN64EPNH8JC6
Awardee CAGE
4B557
Performance District
CA-36
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,243,356 | 100% |
Modified: 5/21/26